欧盟人用药品委员会近期建议批准礼来公司旗下药物Olumiant扩大其适应症范围。该药物活性成分为巴瑞替尼,此次扩大的适应症针对的是青少年重度斑秃患者。此项积极意见意味着Olumiant在欧盟市场用于该新患者群体的监管审批进程向前迈出了关键一步。
欧盟人用药品委员会近期建议批准礼来公司旗下药物Olumiant扩大其适应症范围。该药物活性成分为巴瑞替尼,此次扩大的适应症针对的是青少年重度斑秃患者。此项积极意见意味着Olumiant在欧盟市场用于该新患者群体的监管审批进程向前迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.